NCT05317819 Phase 3 Recruiting
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma Study sponsor: Polaris Group
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2028-09 Estimated
Enrollment · participants 300 Estimated
Source updated 2025-12-18 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology